EVO - Evotec gets $6.6M from Gates Foundation to develop short-regimen TB drugs

2023-03-24 05:15:54 ET

• Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) said it received a $6.6M grant from The Bill & Melinda Gates Foundation to discover and develop drugs for tuberculosis (TB).
• It is a second grant from the foundation to Evotec for TB drug discovery, and would help to discover and develop candidates for a universal, shorter, safer and simpler TB drug regimen, according to the German company.
• The current regimen for drug-sensitive TB requires patients to take multiple drugs for six or more months under clinical monitoring. Those with drug-resistant TB have a longer and complex treatment regimens, with potential side effects, the company added.
• "The grant from The Bill & Melinda Gates Foundation allows us to continue and expand our commitment to global health, to make a meaningful contribution to achieve targets set under the United Nation Sustainable Development Goal (SDG) No 3 and to enable simpler, safer and faster treatment for patients worldwide," said Evotec CEO Werner Lanthaler.

For further details see: